Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach

被引:4
|
作者
Tominaga, Tetsuro [1 ]
Nonaka, Takashi [1 ]
Fukuda, Akiko [2 ]
Shiraisi, Toshio [2 ]
Hashimoto, Shintaro [2 ]
Araki, Masato [2 ]
Sumida, Yorihisa [2 ]
Sawai, Terumitsu [1 ]
Nagayasu, Takeshi [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[2] Sasebo City Gen Hosp, Dept Surg, Nagasaki, Japan
关键词
Laparoscopic surgery; Pelvic exenteration; Transabdominal; Transperineal; Two-team approach; TOTAL MESORECTAL EXCISION; MINIMALLY INVASIVE SURGERY; RECTAL-CANCER; INITIAL-EXPERIENCE; OUTCOMES; RECURRENT; SURVIVAL; TATME;
D O I
10.4174/astr.2021.101.2.102
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: Pelvic exenteration (PE) is a highly invasive procedure with high morbidity and mortality rates. Promising options to reduce this invasiveness have included laparoscopic and transperineal approaches. The aim of this study was to identify the safety of combined transabdominal and transperineal endoscopic PE for colorectal malignancies. Methods: Fourteen patients who underwent combined transabdominal and transperineal PE (T group: 2-team approach, n = 7; O group: 1-team approach, n = 7) for colorectal malignancies between April 2016 and March 2020 in our institutions were included in this study. Clinicopathological features and perioperative outcomes were compared between groups. Results: All patients successfully underwent R0 resection. Operation time tended to be shorter in the T group (463 minutes) than in the O group (636 minutes, P = 0.080). Time to specimen removal was significantly shorter (258 minutes vs. 423 minutes, P = 0.006), blood loss was lower (343 mL vs. 867 mL, P = 0.042), and volume of blood transfusion was less (0 mL vs. 560 mL, P = 0.063) in the T group, respectively. Postoperative complications were similar between groups. Conclusion: Combined transabdominal and transperineal PE under a synchronous 2-team approach was feasible and safe, with the potential to reduce operation time, blood loss, and surgeon stress. [Ann Surg Treat Res 2021;101(2):102-110]
引用
收藏
页码:102 / 110
页数:9
相关论文
共 35 条
  • [31] Feasibility of needlescopic surgery for colorectal cancer: safety and learning curve for Japanese Endoscopic Surgical Skill Qualification System-unqualified young surgeons
    Hisanori Miki
    Yosuke Fukunaga
    Toshiya Nagasaki
    Takashi Akiyoshi
    Tsuyoshi Konishi
    Yoshiya Fujimoto
    Satoshi Nagayama
    Masashi Ueno
    Surgical Endoscopy, 2020, 34 : 752 - 757
  • [32] Antiangiogenic effects, safety and feasibility of two different capecitabine/Oxaliplatin-based schedules in elderly colorectal cancer patients.
    Carreca, Ignazio Ugo
    Bronte, Giuseppe
    Burgio, Marco
    Piazza, Dario
    Rizzo, Sergio
    Russo, Salvatore
    Tartaglia, Laura
    Cigno, Anna
    Balducci, Lodovico
    CANCER RESEARCH, 2006, 66 (08)
  • [33] Safety and surgical outcomes of transoral endoscopic thyroidectomy vestibular approach for papillary thyroid cancer: A two-centre study
    Zheng, Guibin
    Ma, Chi
    Sun, Haiqing
    Wu, Guochang
    Guo, Yawen
    Wu, Guoyang
    Zheng, Haitao
    EJSO, 2021, 47 (06): : 1346 - 1351
  • [34] Capecitabine (XEL) plus Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings
    Carreca, I. U.
    Rizzo, S.
    Bronte, G.
    Burgio, M.
    Fiorino, S.
    Maggio, G.
    Cigno, A.
    Carreca, A. R.
    Russo, S.
    Piazza, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 373 - 373
  • [35] Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years
    Moriwaki, Toshikazu
    Nishina, Tomohiro
    Sakai, Yoshinori
    Yamamoto, Yoshiyuki
    Shimada, Mitsuo
    Ishida, Hiroyasu
    Amagai, Kenji
    Sato, Mikio
    Endo, Shinji
    Negoro, Yuji
    Kuramochi, Hidekazu
    Denda, Tadamichi
    Hatachi, Yukimasa
    Ikezawa, Kazuto
    Nakajima, Go
    Bando, Yoshiaki
    Tsuji, Akihito
    Yamamoto, Yuji
    Morimoto, Masamitsu
    Kobayashi, Kazuma
    Hyodo, Ichinosuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (07) : 717 - 726